Login Form



Phase I Trials

Print

OPEN TO ENROLLMENT

1.  A Rollover Study to Provide Continued Treatment with GSK2118436 to Subjects with BRAF Mutation-Positive Tumors

This rollover study is designed to provide continued access to GSK2118436 for eligible subjects with BRAF mutation-positive tumors who have previously participated in a GlaxoSmithKline-sponsored GSK2118436 study (parent study), who have no evidence of progressive disease and who have tolerated GSK2118436 in the parent study without significant toxicities.

2.  Study of the Safety and Pharmacokinetics of MPDL3280A Administered Intravenously As a Single Agent to Patients With Locally Advanced or Metastatic Solid Tumors
This Phase I, multicenter, first in human, open-label, dose escalation study will evaluate the safety, tolerability, and pharmacokinetics of MPDL3280A administered as single agent by intravenous (IV) infusion to patients with locally advanced or metastatic solid malignancies.

3.  GSK1120212 Rollover Study
This is an open-label study which will permit subjects with solid tumors or leukemia, who are currently clinically benefitting on another GSK sponsored trial with GSK1120212 either monotherapy or in combination continued access to GSK1120212.

4. Study of ABT-165 in Subjects With Advanced Solid Tumors
This is a Phase 1/1b open-label study evaluating the safety, pharmacokinetics (PK), and preliminary efficacy of ABT-165 in subjects with advanced solid tumors. The early clinical development plan for ABT-165 is based on the activity demonstrated in preclinical models.

5.  A Study of LY3164530 in Participants With Cancer
The main purpose of this study is to evaluate the safety of a study drug known as LY3164530 in participants with cancer that is advanced and/or has spread to another part(s) of the body. The study drug will be given by slow drip into a vein once every 14 days.

6.   A Phase I, Open-Label Study of MOXR0916 in Patients With Locally Advanced or Metastatic Solid Tumors
This is a first-in-human, Phase I, open-label, multicenter, dose-escalation stud y designed to evaluate the safety, tolerability, and pharmacokinetics of MOXR091 6 administered intravenously in patients with locally advanced or metastatic sol id tumors that have progressed after all available standard therapy or for which standard therapy has proven to be ineffective or intolerable, or is considered inappropriate. The planned duration of the study is approximately 3 years.

7.  A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors
This is a multicenter, open-label, dose-exploration and dose-expansion study to evaluate the safety, tolerability, antitumor activity, PK and immunogenicity of MEDI4736 in combination with tremelimumab in subjects with select advanced solid tumors.

8.  A Phase 1 Study of OMP-305B83 in Subjects With Solid Tumors
This is an open-label Phase 1 dose escalation and expansion study of OMP-305B83 in subjects with previously treated solid tumors. Study includes a dose escalation phase and expansion phase. Subjects will be assessed for safety, immunogenicity, pharmacokinetics, biomarkers, and efficacy.

9.  Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
This is an open-label, dose-escalation Phase 1/2 study to assess the safety of ASTX660, determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), and recommended dosing regimen, and to obtain preliminary efficacy, pharmacokinetic (PK), and target engagement data, in subjects with advanced solid tumors or lymphoma for which standard curative measures do not exist or are no longer effective.

10.  A Dose-Escalation Study of the Safety and Pharmacokinetics of MOXR0916 and MPDL3280A in Patients With Locally Advanced or Metastatic Solid Tumors
This open-label, dose-escalation study will evaluate the safety, tolerability, and pharmacokinetics of the combination of MOXR0916 and MPDL3280A in patients with locally advanced, recurrent, or metastatic incurable solid malignancy that has progressed after available standard therapy, or for which standard therapy has proven to be ineffective or intolerable, or is considered inappropriate; or for which a clinical trial of an investigational agent is a recognized standard of care.

11.  A Study of GDC-0919 and MPDL3280A Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors
This study will evaluate the safety, tolerability, and pharmacokinetics of the combination of GDC-0919 and MPDL3280A in participants with locally advanced, recurrent, or metastatic incurable solid malignancy that has progressed after available standard therapy or for which standard therapy is ineffective, intolerable, or inappropriate. Participants will be enrolled in two stages, including a dose-escalation stage and an expansion stage.

12.  A Study to Assess the Safety and Tolerability of MPDL3280A in Combination With Other Immune-modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors
This global, multicenter, open-label study will evaluate the safety and tolerability of MPDL3280A in combination with other immune-modulating therapies in the treatment of selected advanced or metastatic malignancies. The MPDL3280A plus ipilimumab arm (Arm A) will focus primarily on patients with advanced or metastatic NSCLC. The MPDL3280A plus interferon alfa-2b arm (Arm B) will enroll patients with advanced or metastatic RCC and melanoma. MPDL3280A will be administered intravenously every 3 weeks (q3w).

13.  ACY 241 in Combination With Paclitaxel in Patients With Advanced Solid Tumors
This is a Phase 1b, multicenter, single arm, open label, dose escalation study to determine the MTD and evaluate the safety and preliminary antitumor activity of orally (PO) administered ACY 241 in combination with intravenously (IV) administered paclitaxel in eligible patients with advanced solid tumors.

14.  Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
This first-in-human open-label, multicenter, dose-escalation study is designed to evaluate the safety, tolerability, and PK of MTIG7192A alone or in combination with atezolizumab in participants with locally advanced, recurrent, or metastatic incurable tumors for whom standard therapy does not exist, has proven to be ineffective or intolerable, or is considered inappropriate, or for whom a clinical trial of an investigational agent is a recognized standard of care.

15.  A Study of Durvalumab (MEDI4736) and IPH2201 in Solid Tumors
This is a multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, antitumor activity, PK, pharmacodynamics, and immunogenicity of Durvalumab (MEDI4736) in combination with IPH2201 in Adult Subjects with selected advanced solid tumors.